Table 3. Acute toxicities in 2 groups.
| Toxicity | NACT+CCRT (n=73) | CCRT (n=68) | χ2 | p-value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade0 No. | Grade1 No. | Grade2 No. | Grade3 No. | Grade4 No. | Grade0 No. | Grade1 No. | Grade2 No. | Grade3 No. | Grade4 No. | ||||
| Hematologic | |||||||||||||
| Leukocyte | 7 | 0 | 18 | 41 | 7 | 4 | 4 | 16 | 39 | 5 | 1.504 | 0.222 | |
| Neutropenia | 13 | 6 | 21 | 27 | 6 | 11 | 4 | 22 | 24 | 7 | 0.067 | 0.796 | |
| Anemia | 3 | 7 | 33 | 29 | 1 | 1 | 13 | 30 | 23 | 1 | 0.241 | 0.624 | |
| Thrombocytopenia | 25 | 17 | 19 | 9 | 3 | 26 | 15 | 18 | 7 | 2 | 4.110 | 0.045 | |
| Radiation | |||||||||||||
| Proctitis | 62 | 5 | 5 | 1 | 0 | 54 | 8 | 6 | 3 | 2a | 9.612 | 0.001 | |
| Cystitis | 63 | 6 | 3 | 0 | 0 | 60 | 4 | 3 | 1 | 0 | 4.000 | 0.047 | |
| Nausea/vomiting | 19 | 35 | 16 | 3 | 0 | 18 | 26 | 20 | 4 | 0 | 1.611 | 0.206 | |
| Constipation | 73 | 0 | 0 | 0 | 0 | 66 | 1 | 1 | 0 | 0 | 0.821 | 0.402 | |
| Abdominal pain | 65 | 7 | 1 | 0 | 0 | 56 | 9 | 2 | 1 | 0 | 7.767 | 0.006 | |
| Liver toxicity | 39 | 25 | 8 | 1 | 0 | 45 | 26 | 6 | 1 | 0 | 0.609 | 0.437 | |
| Renal toxicity | 57 | 16 | 0 | 0 | 0 | 44 | 22 | 1 | 1 | 0 | 6.889 | 0.010 | |
| Fatigue | 18 | 29 | 26 | 0 | 0 | 12 | 27 | 29 | 0 | 0 | 2.203 | 0.079 | |
Toxicity was measured weekly while in the study and again 30 days after the last study treatment. Five patients in the CCRT group had a severe adverse event after starting treatment, so they stopped early. Consequently, 68 patients with other toxic side effects were analyzed.
CCRT, concurrent chemoradiotherapy; NACT+CCRT, neoadjuvant chemotherapy combined with concurrent chemoradiotherapy.